Has Ian Krop, MD received payments from drug or device companies?

Yes. Drug and device makers reported $219,155 in general payments to Ian Krop, MD across 148 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ian Krop, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ian Krop, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ian Krop, MD

Medical Oncology · New Haven, CTNPI 1033187455

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $171,700 of the $219,155 with a category attached, or 78.3%. It is spread thinly across 21 manufacturers, the largest accounting for just 20.6%. 2025 is the largest year on record at $57,161, 2.3 times the $24,528 reported in 2019. Among medical oncology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$219,155in general payments, 2019–2025

Across 148 payments — averaging $1480.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$45K
AstraZeneca$34K
Astrazeneca UK Limited$32K
Merck Healthcare Kgaa$20K
EMD Serono Research & Development Institute, Inc.$14K
Merck$14K
plus $59K from 15 others

$7,356,847in research payments, 2019–2025

Across 706 payments — averaging $10,420 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Daiichi Sankyo Inc.$3.4M
Daiichi Sankyo Company LTD$1.8M
Genentech, Inc.$1.1M
Pfizer$610K
Seagen Inc.$269K
Medivation LLC.$205K
plus $36K from 4 others

What the payments were for

Consulting fees$171,70078%
Speaking & faculty fees$19,6439%
Grants$3500%
Travel & lodging$24,66311%
Food & beverage$2,7871%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	39	$45,081
AstraZeneca	22	$33,635
Astrazeneca UK Limited	13	$32,087
Merck Healthcare Kgaa	5	$20,200
EMD Serono Research & Development Institute, Inc.	2	$14,481
Merck	8	$14,250
E.r. Squibb & Sons, L.L.C.	14	$11,208
Novartis	7	$10,094
Pfizer	6	$5,561
Eli Lilly	4	$5,439
Boehringer Ingelheim International GmbH	2	$4,515
Genentech USA, Inc.	6	$4,157
Seagen Inc.	2	$4,138
Puma Biotechnology, Inc.	4	$3,921
F. Hoffmann-la Roche AG	6	$3,715
Chugai Pharmaceutical Co., Ltd.	1	$2,530
Janssen Research & Development, LLC	1	$2,400
Macrogenics, Inc.	1	$1,500
Roche Products Limited	3	$119
Caris MPI, Inc.	1	$113
Gilead	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Enhertu$39,192
KEYTRUDA$12,500
Kadcyla$7,720
Perjeta$7,395
Herceptin$6,950
KISQALI$5,194
DATROWAY$4,795
Phesgo$3,280
PIQRAY$2,813
TUKYSA$2,700
Truqap$2,460
Non-Covered Product$2,130
MARGENZA$1,500
TECENTRIQ$1,140
MI CANCER SEEK$113

How this compares

$219,155 in reported general payments places this provider in the 90th percentile of 79 medical oncology providers in Connecticut.

See all medical oncology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$8,495

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Letrozole	32	$596

Paid to pharmacies, not to this prescriber.

Other medical oncology in New Haven

Peter MarksNew Haven$578K
Daniel PetrylakNew Haven$446K
Mandar MuzumdarNew Haven$371K
Barbara BurtnessNew Haven$297K
Francine FossNew Haven$193K
Anne ChiangNew Haven$158K
Mario SznolNew Haven$157K
Lajos PusztaiNew Haven$152K
Howard HochsterNew Haven$133K
Sarah GoldbergNew Haven$131K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →